13F Pro quality score
Rank #2,790 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Entera Bio Ltd.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $42.0K | $-11.4M | — |
| FY 2024 | 10-K | $181.0K | $-9.5M | — |
| FY 2022 | 10-K | $134.0K | $-13.1M | — |
| FY 2021 | 10-K | $571.0K | $-12.2M | — |
| FY 2020 | 10-K | $365.0K | $-11.2M | — |
| FY 2019 | 20-F | $236.0K | $-10.8M | — |
Entera Bio Ltd. (ENTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENTX at 17.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,790 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Entera Bio Ltd. reports net income of $-7.3M, free cash flow of $-3.5M. ENTX trades on the Nasdaq exchange and files with the SEC under CIK 1638097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Entera Bio Ltd. directly from SEC EDGAR.